American Oncology Network (AONCW) is a relatively new player in the US oncology services market. While the company has yet to gain significant market traction since its 2021 IPO, a closer look at its financials reveals a company that is, at the very least, interesting.

AONCW's financial performance has been mixed since its IPO. Revenue has grown, however the company is still operating in the red.

Without more qualitative information about the company, such as the content found in quarterly earnings call transcripts or presentations, it's hard to say what's in store for AONCW. Investors would be wise to seek out information on the following:

Is the company investing in growth? Is this impacting profitability?

What is management's long-term vision for the company?

What are the risks and opportunities facing AONCW?

The use of chemotherapy to treat cancer dates back to World War II, where scientists discovered that nitrogen mustard, a chemical warfare agent, could kill rapidly dividing cells, including cancer cells. This finding laid the groundwork for the development of modern chemotherapy drugs.